FCGR1A and autoimmune thrombocytopenic purpura: In the monocytes of ITP patients treated with ONX-0914, FcγRIII (CD16) expression was found to be significantly decreased compared to DMSO-treated controls (P<0.01), while these treatments had no significant impact on FcγRI (CD64) expression (Figure 3B).